Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Metastatic Breast Cancer, HER2 Low Breast Carcinoma
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
The goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast…
- Conditions
- Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer, Breast Cancer
- Trial name
- ERADICATE (NCT07198724)
- Testing
- Elacestrant, Trastuzumab Deruxtecan
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Kristina A. Fanucci
Breast Cancer
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
The following trial is designed to offer pre-approval drug access to iniparib in combination with gemcitabine and carboplatin in order to provide potential clinical benefit to patients with ER-, PR-, and HER2-negative metastatic…
- Trial name
- NCT01130259
- Testing
- iniparib
- Sponsor
- Sanofi
Breast Cancer
Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer
National, randomized, unblinded, phase IIb trial with 2 strata: First-line chemotherapy / Second-line chemotherapy for locally recurrent or metastatic breast cancer.
- Trial name
- VAROCE (NCT01658462)
- Testing
- Docetaxel, Nintedanib, Docetaxel: increase of the dose
- Where
- 12 sites in France
- Volunteers
- 51 people
- Sponsor
- Centre Oscar Lambret
Breast Cancer
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00176488
- Testing
- epirubicin, vinorelbine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
HER2/Neu Positive, Invasive Breast Carcinoma
Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
This phase I trial studies the side effects and best dose of entinostat when given together with lapatinib ditosylate and trastuzumab in treating patients with breast cancer that has spread from the original (primary) tumor to…
- Conditions
- HER2/Neu Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01434303
- Testing
- Entinostat, Laboratory Biomarker Analysis, Lapatinib Ditosylate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Breast Neoplasms, Breast Cancer
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
Background: Human epidermal growth factor receptor 2 (HER2, also known as c-erbB2 or neu)/neu (HER2) is a tumor protein that appears in almost a third of breast cancers and in several other types of cancers such as colon…
- Conditions
- Breast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu Expression
- Trial name
- NCT01730118
- Testing
- Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in patients with advanced cancers - melanoma, lung, breast and glioblastoma multiforme (GBM) involving the CNS during…
- Trial name
- DM-CHOC-PEN (NCT02038218)
- Testing
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- DEKK-TEC, Inc.
Metastatic Lung Cancer, Metastatic Breast Cancer
The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel
Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer.
- Conditions
- Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Metastatic Prostate Cancer
- Trial name
- NCT01814150
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Gottfried Maya
Metastatic Cancer, Breast Cancer
Biomarkers to Detect Endocrine Therapy Resistance
This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy.
- Conditions
- Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
- Trial name
- NCT06067503
- Testing
- 18F-fluorofuranylnorprogesterone, Liquid Biopsy, Positron Emission Tomography/Computed Tomography
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Breast Cancer
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer.
- Trial name
- NCT02980341
- Testing
- Patritumab Deruxtecan
- Where
- 26 sites in United States, Japan
- Volunteers
- 182 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Metastatic Breast Cancer
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
This is a proof-of-concept study to define efficacy of vinorelbine, cisplatin, disulfiram and copper in CTC_EMT positive refractory metastatic hormone receptor positive, HER2 negative breast cancer.
- Trial name
- NCT04265274
- Testing
- Disulfiram, Vinorelbin, Cisplatin
- Where
- Slovakia
- Sponsor
- National Cancer Institute, Slovakia
Breast Cancer, Chemotherapeutic Agent Toxicity
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
RATIONALE: Gathering information over time from laboratory tests, imaging scans, and assessment tests may help doctors learn more about the side effects of chemotherapy and plan the best treatment.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue
- Trial name
- NCT00755313
- Testing
- trastuzumab, aromatase inhibition therapy, carboplatin
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Breast Cancer, Metastatic Breast Cancer
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer.
- Trial name
- ELEVATE (NCT05563220)
- Testing
- Elacestrant, Alpelisib, Everolimus
- Where
- 83 sites in United States, Argentina and 11 more
- Volunteers
- 435 people
- Sponsor
- Stemline Therapeutics, Inc.
Breast Cancer
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
This is a multicenter phase 2 study designed to evaluate the safety and efficacy of eribulin mesylate in combination with trastuzumab as first line treatment in female subjects with locally recurrent or metastatic human epidermal…
- Trial name
- NCT01269346
- Testing
- Eribulin Mesylate
- Where
- 26 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eisai Inc.
Triple Negative Breast Cancer
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO) plus electroporation (EP) in combination with pembrolizumab therapy.
- Trial name
- NCT03567720
- Testing
- tavokinogene telseplasmid, Pembrolizumab, Immunopulse
- Where
- 14 sites in United States, Australia
- Volunteers
- 65 people
- Sponsor
- OncoSec Medical Incorporated
Breast Cancer, Metastases
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.
- Trial name
- NCT00080262
- Testing
- Ixabepilone
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 125 people
- Sponsor
- R-Pharm
Breast Cancer, Colorectal Cancer
Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer
RATIONALE: Collecting information over time about patients' and health care providers' understanding of pain and fatigue and providing education about pain and fatigue management may improve quality of life.
- Conditions
- Breast Cancer, Colorectal Cancer, Fatigue, Lung Cancer
- Trial name
- NCT00900835
- Testing
- educational intervention, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United States
- Volunteers
- 470 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women
RATIONALE: Learning about the reasons for choosing to have, or not to have, breast reconstruction after mastectomy for breast cancer may help doctors understand why black or Latina women may or may not undergo breast…
- Trial name
- NCT00519974
- Testing
- counseling intervention, study of socioeconomic and demographic variables, management of therapy complications
- Where
- 6 sites in United States
- Volunteers
- 55 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Neoplasms
Pembrolizumab and Paclitaxel in Hypermutated Breast Cancer
Abbreviated Title: Pembrolizumab in hypermutated breast cancer Trial Phase: II Clinical Indication: Hormone receptor-positive metastatic breast cancer Trial Type: Interventional Type of control: None Route of administration…
- Trial name
- NCT03492918
- Testing
- Pembrolizumab, paclitaxel
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Yonsei University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.